睿知中国医院研究地图
候选清单

即将招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

TR115 in ARID1A-Mutated Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07793318,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed advanced solid tumor with ARID1A mutation.

    入选标准第 3 条

  3. Cohort 1: Platinum-resistant ovarian/fallopian tube/peritoneal clear cell carcinoma with disease progression after ≥1 prior platinum-based regimen. Cohort 2: Endometrial cancer with disease progression after ≥1 prior platinum-based regimen and prior immunotherapy failure or intolerance. Cohort 3: Other advanced solid tumors (including gastric cancer, urothelial carcinoma) with disease progression after ≥1 prior standard systemic therapy.

    入选标准第 4 条

    Prior treatment with EZH2 or EZH1/2 inhibitors resulting in disease progression (intolerance permitted).

    排除标准第 1 条

    Prior anti-tumor therapy-related adverse events not recovered to ≤Grade 1 (CTCAE v6.0), except alopecia or peripheral neuropathy Grade ≤2.

    排除标准第 13 条

  4. ECOG performance status 0-1.

    入选标准第 5 条

  5. At least one measurable lesion per RECIST v1.1.

    入选标准第 7 条

  6. Active hepatitis B or C requiring treatment, or HIV infection.

    排除标准第 8 条

    Other primary malignancy within 5 years, except cured non-melanoma skin cancer, carcinoma in situ, or thyroid carcinoma.

    排除标准第 12 条

  7. Male and female participants of childbearing potential must agree to use medically approved contraception during the study and for 6 months after the last dose.

    入选标准第 10 条

    Pregnancy, lactation, or positive pregnancy test.

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07793318,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Able to understand and provide written informed consent.
  2. Age 18 to 70 years, inclusive.
  3. Histologically or cytologically confirmed advanced solid tumor with ARID1A mutation.
  4. Cohort 1: Platinum-resistant ovarian/fallopian tube/peritoneal clear cell carcinoma with disease progression after ≥1 prior platinum-based regimen. Cohort 2: Endometrial cancer with disease progression after ≥1 prior platinum-based regimen and prior immunotherapy failure or intolerance. Cohort 3: Other advanced solid tumors (including gastric cancer, urothelial carcinoma) with disease progression after ≥1 prior standard systemic therapy.
  5. ECOG performance status 0-1.
  6. Life expectancy ≥3 months.
  7. At least one measurable lesion per RECIST v1.1.
  8. Adequate organ function: ANC ≥1.5×10⁹/L, PLT ≥100×10⁹/L, Hb ≥100 g/L (no growth factor or transfusion support within 14 days prior to first dose), TBIL ≤1.5×ULN, ALT/AST ≤2.5×ULN (≤5×ULN if liver metastasis), CrCl ≥50 mL/min, LVEF ≥50%, QTcF <450 ms (male) or <470 ms (female).
  9. Willing to provide archival or fresh tumor tissue for biomarker analysis.
  10. Male and female participants of childbearing potential must agree to use medically approved contraception during the study and for 6 months after the last dose.

排除标准:Exclusion Criteria:

  1. Prior treatment with EZH2 or EZH1/2 inhibitors resulting in disease progression (intolerance permitted).
  2. Third-space fluid accumulation not controllable by drainage or other means.
  3. Systemic corticosteroid therapy (>10 mg/day prednisone or equivalent) within 14 days prior to first dose, except for inhaled or topical use.
  4. Inability to swallow oral medication or conditions significantly affecting drug absorption.
  5. Known central nervous system (CNS) involvement.
  6. Tumor invasion or encasement of major vessels.
  7. Active infection requiring systemic therapy.
  8. Active hepatitis B or C requiring treatment, or HIV infection.
  9. Active autoimmune disease requiring systemic immunosuppressive therapy.
  10. Significant cardiovascular disease (e.g., myocardial infarction within 6 months, NYHA Class III/IV heart failure, uncontrolled arrhythmia).
  11. Pregnancy, lactation, or positive pregnancy test.
  12. Other primary malignancy within 5 years, except cured non-melanoma skin cancer, carcinoma in situ, or thyroid carcinoma.
  13. Prior anti-tumor therapy-related adverse events not recovered to ≤Grade 1 (CTCAE v6.0), except alopecia or peripheral neuropathy Grade ≤2.
  14. Use of strong or moderate CYP3A4 inhibitors/inducers within 14 days prior to first dose.
  15. Any other condition that in the investigator's opinion makes the participant unsuitable for the study.

引自 ClinicalTrials.gov, NCT07793318, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07793318,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07793318